Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334004 · ClinicalTrials.gov registry record · Phase 1
Lopinavir/Ritonavir in PLWH With High-Grade AIN
A Phase 1 study of High-Grade Anal Intraepithelial Neoplasia, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05334004 is a Phase 1 study of High-Grade Anal Intraepithelial Neoplasia that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05334004, a Phase 1 study of High-Grade Anal Intraepithelial Neoplasia, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.
Conditions Studied
Interventions
- DRUG Lopinavir / Ritonavir
Study Locations (1)
Wisconsin
- UW Digestive Health Center Anoscopy Clinic - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05334004
The ClinicalTrials.gov registry entry for NCT05334004 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-Grade Anal Intraepithelial Neoplasia appearing as the primary indexed condition, and to 1 intervention - of which Lopinavir / Ritonavir is the first listed.
NCT05334004 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05334004 about?
NCT05334004 is a clinical study titled "Lopinavir/Ritonavir in PLWH With High-Grade AIN". This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.
What is the current status of trial NCT05334004?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-12-19. Estimated completion is 2026-06.
What conditions does trial NCT05334004 study?
This clinical trial studies the following conditions: High-Grade Anal Intraepithelial Neoplasia.
What interventions are being tested in trial NCT05334004?
The interventions under investigation include: Lopinavir / Ritonavir (DRUG).
Who is sponsoring clinical trial NCT05334004?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05334004 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.